Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2017 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS

– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...